Reviews
EHA Guidelines and COSMIN Systematic Review on Patient-Reported Outcomes in Ph-Negative MPN Trials
Oliva et alHemaSphere

The European Hematology Association (EHA) guidelines address the selection, use, and reporting of patient-reported outcome measures (PROMs) in clinical trials of classical Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-negative MPNs), comprising myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PROMs are increasingly incorporated into these trials as primary, key secondary, secondary, or exploratory endpoints.
A COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) systematic review identified that PRO assessment was planned or reported in 79 of 87 randomized controlled trials (91%), but published PRO results were available for only 46 of those 79 studies (58%). Evaluating 52 reports examining the measurement properties of 12 PROMs in classical Ph-negative MPNs, the review identified uneven evidence across instruments: • Myelofibrosis Symptom Assessment Form (MF-SAF) v4.0 had the strongest measurement-property evidence for MF symptom burden, with sufficient structural validity and internal consistency with high certainty, alongside inconsistent findings for reliability, construct validity, and responsiveness. • Myelofibrosis Symptom Diary (MPN-SD) had the best content-validity evidence, with limited evidence across other measurement properties. • MPN-10/MPN-SAF total symptom score (TSS) has substantial clinical-trial experience and clinical familiarity, including use in pivotal development programs, though formal content-validity evidence and certain structural and construct-validity findings remain limited or inconsistent. • Generic and cancer-specific tools, including the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the EuroQol 5-Dimension instrument (EQ-5D), remain useful for broader health-related quality of life and health-utility evaluations, but the authors state they should not be used alone to support MPN-specific symptom claims.
The guidelines adapt established oncology PRO standards to MPN-specific instrument, subtype, endpoint, timing, and interpretation considerations. The authors recommend fit-for-purpose PROM selection, standardized self-administration, baseline and longitudinal assessments aligned with trial objectives, prospective missing-data mitigation, PRO-endpoint sample-size planning, and transparent reporting in accordance with CONSORT-PRO and related standards.
Key Takeaways
- In a COSMIN systematic review of classical Ph-negative MPN randomized controlled trials, PRO assessment was planned or reported in 79 of 87 trials (91%), but published PRO results were reported for only 46 of those 79 studies (58%).
- Among 12 evaluated PROMs, MF-SAF v4.0 had the strongest measurement-property evidence for MF symptom burden with high-certainty structural validity and internal consistency, whereas the guidelines state generic tools like EORTC QLQ-C30 and EQ-5D should not be used alone to support MPN-specific symptom claims.
Read the original sourceHemaSphere
